Show simple item record

dc.contributor.authorRashidian, Mohammad
dc.contributor.authorBagnato, Aaron
dc.contributor.authorDongre, Anushka
dc.contributor.authorReinhardt, Ferenc
dc.contributor.authorKeckesova, Zuzana
dc.contributor.authorPloegh, Hidde
dc.contributor.authorWeinberg, Robert A
dc.date.accessioned2018-07-12T19:54:04Z
dc.date.available2018-07-12T19:54:04Z
dc.date.issued2017-04
dc.date.submitted2017-02
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.urihttp://hdl.handle.net/1721.1/116958
dc.description.abstractThe epithelial-to-mesenchymal transition (EMT) is a cell biological program that confers mesenchymal traits on carcinoma cells and drives their metastatic dissemination. It is unclear, however, whether the activation of EMT in carcinoma cells can change their susceptibility to immune attack. We demonstrate here that mammary tumor cells arising from more epithelial carcinoma cell lines expressed high levels of MHC-I, low levels of PD-L1, and contained within their stroma CD8þT cells and M1 (antitumor) macrophages. In contrast, tumors arising from more mesenchymal carcinoma cell lines exhibiting EMT markers expressed low levels of MHC-I, high levels of PD-L1, and contained within their stroma regulatory T cells, M2 (protumor) macrophages, and exhausted CD8þT cells. Moreover, the more mesenchymal carcinoma cells within a tumor retained the ability to protect their more epithelial counterparts from immune attack. Finally, epithelial tumors were more susceptible to elimination by immunotherapy than corresponding mesenchymal tumors. Our results identify immune cells and immunomodulatory markers that can be potentially targeted to enhance the susceptibility of immunosuppressive tumors to various therapeutic regimens.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant P01-CA080111)en_US
dc.publisherAmerican Association for Cancer Research (AACR)en_US
dc.relation.isversionofhttp://dx.doi.org/10.1158/0008-5472.CAN-16-3292en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourcePMCen_US
dc.titleEpithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomasen_US
dc.typeArticleen_US
dc.identifier.citationDongre, Anushka, et al. “Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas.” Cancer Research 77, 15 (April 2017): 3982–3989 © 2017 American Association for Cancer Researchen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.departmentLudwig Center for Molecular Oncology (Massachusetts Institute of Technology)en_US
dc.contributor.mitauthorDongre, Anushka
dc.contributor.mitauthorReinhardt, Ferenc
dc.contributor.mitauthorKeckesova, Zuzana
dc.contributor.mitauthorPloegh, Hidde
dc.contributor.mitauthorWeinberg, Robert A
dc.relation.journalCancer Researchen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2018-07-12T14:39:42Z
dspace.orderedauthorsDongre, Anushka; Rashidian, Mohammad; Reinhardt, Ferenc; Bagnato, Aaron; Keckesova, Zuzana; Ploegh, Hidde L.; Weinberg, Robert A.en_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-1090-6071
dc.identifier.orcidhttps://orcid.org/0000-0002-0895-3557
mit.licenseOPEN_ACCESS_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record